Vimarsana
Biggest News Aggregation in the World

Page 28 - David Ricks News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from David Ricks. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In David Ricks Today - Breaking & Trending Today

BioAsia 2024 set to host 3000+ Delegates from 50 Countries in the 21st Edition - Vimarsana News

BioAsia 2024 set to host 3000+ Delegates from 50 Countries in the 21st Edition

NL Correspondent Jammu Tawi: BioAsia - the marquee healthcare and Life Sciences event, organized by the Government of Telangana, is all set for the grand unveiling of its 21st edition in Hyderabad.Sri Duddilla Sridhar Babu, Minister for Information Technology, Industries & Commerce conducted a comprehensive review of the preparations for the upcoming global conference. As

BioAsia 2024 set to host 3000+ Delegates from 50 Countries: Data and AI to Command Center Stage in the 21st Edition - Vimarsana News

BioAsia 2024 set to host 3000+ Delegates from 50 Countries: Data and AI to Command Center Stage in the 21st Edition

New Delhi : BioAsia - the marquee healthcare and Life Sciences event, organized by the Government of Telangana, is all set for the grand unveiling of its 21st edition in Hyderabad. Sri Duddilla Sridhar Babu, Minister for Information Technology, Indus

Drugmakers Plot Way Into Obesity Market With Deals and Development - Vimarsana News

Drugmakers Plot Way Into Obesity Market With Deals and Development

Pharmaceutical executives from Amgen to Pfizer are plotting to break into the lucrative obesity market by developing or cutting deals to acquire better drugs that will...

Drugmakers plot way into obesity market with deals and development - Vimarsana News

Drugmakers plot way into obesity market with deals and development

Pharmaceutical executives from Amgen to Pfizer are plotting to break into the lucrative obesity market by developing or cutting deals to acquire better drugs that will compete with Novo Nordisk's Wegovy and Zepbound from Eli Lilly. Amgen has an experimental dual mechanism obesity drug in mid-stage trials it hopes will have fewer side effects with less frequent dosing than Wegovy or Zepbound, Chief Scientific Officer Jay Bradner told Reuters at the annual JPMorgan health conference in San Francisco this week.

Source: yahoo.com
JPM24: 'Diabesity' duopoly between Novo, Lilly takes center stage - Vimarsana News

JPM24: 'Diabesity' duopoly between Novo, Lilly takes center stage

The CEOs of Eli Lilly and Novo Nordisk addressed nagging questions at the 2024 J.P. Morgan Healthcare Conference.